Methods: According to the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition) released in 2023, relevant databases such as PubMed, Cochrane, and Embase, drug labels, and clinical guidelines were searched for drug information
Reporting Side Effects Through the MHRA Yellow Card Scheme Suspected side effects from retatrutide used outside a clinical trial should be reported via the MHRA Yellow Card Scheme
Coryell Health doesnt recommend taking GLP-1 medications if you: Are pregnant or breastfeeding Have a personal or family history of medullary thyroid cancer (MTC) Have a diagnosis of multiple endocrine neoplasia syndrome type 2 Have a history of pancreatitis Have severe gastrointestinal conditions Side effects of taking a GLP-1 medication may include: Loss of appetite Nausea and vomiting Diarrhea Dizziness Mildly increased heart rate Pancreatitis Medullary thyroid cancer (MTC) Acute kidney injury If youre unsure whether an existing condition, your personal history or your family history will not mix well with a GLP-1 medication, talk with your Coryell Health primary care provider to determine whether a GLP-1 medication is right for you
And they do all of this without requiring the extreme calorie restriction that would compromise milk supply or recovery
That suggests the final number in longer trials could be even higher
